Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDYMION 2 long-term extension of soticlestat in Dravet syndrome or Lennox-Gastaut syndrome
NL-OMON53987Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of soticlestat in Dravet syndrome and Lennox-Gastaut syndrome (LGS) (2 cohorts), sponsored by Takeda. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of abnormal clinical laboratory and ECG values and 4 more. Started Jun 2022; status: recruiting.
02
Drugs
soticlestat
03
Conditions
Dravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on NL-OMON53987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53987.